These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24855208)

  • 21. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytarabine-Resistant
    Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
    Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
    J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.
    Wu M; Hamaker M; Li L; Small D; Duffield AS
    Leukemia; 2017 Mar; 31(3):688-696. PubMed ID: 27748370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.
    Scholl S; Melle C; Bleul A; Spies-Weisshart B; Kunert C; Höffken K; von Eggeling F
    Leuk Lymphoma; 2007 Dec; 48(12):2418-23. PubMed ID: 18067018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
    Zhou L; Fu L; Lv N; Chen XS; Liu J; Li Y; Xu QY; Huang S; Zhang XD; Dou LP; Wang LL; Li YH; Yu L
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(4):786-794. PubMed ID: 28272704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
    Godfrey R; Arora D; Bauer R; Stopp S; Müller JP; Heinrich T; Böhmer SA; Dagnell M; Schnetzke U; Scholl S; Östman A; Böhmer FD
    Blood; 2012 May; 119(19):4499-511. PubMed ID: 22438257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
    Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
    J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting RIPK1 in AML cells carrying FLT3-ITD.
    Hillert LK; Bettermann-Bethge K; Nimmagadda SC; Fischer T; Naumann M; Lavrik IN
    Int J Cancer; 2019 Sep; 145(6):1558-1569. PubMed ID: 30828789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.
    Lopez S; Voisset E; Tisserand JC; Mosca C; Prebet T; Santamaria D; Dubreuil P; De Sepulveda P
    Oncotarget; 2016 Aug; 7(32):51163-51173. PubMed ID: 27323399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.
    Oellerich T; Mohr S; Corso J; Beck J; Döbele C; Braun H; Cremer A; Münch S; Wicht J; Oellerich MF; Bug G; Bohnenberger H; Perske C; Schütz E; Urlaub H; Serve H
    Blood; 2015 Mar; 125(12):1936-47. PubMed ID: 25605370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells.
    Abe M; Pelus LM; Singh P; Hirade T; Onishi C; Purevsuren J; Taketani T; Yamaguchi S; Fukuda S
    PLoS One; 2016; 11(7):e0158290. PubMed ID: 27387666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.